Castle Biosciences (CSTL) Peer Comparison

$33.44

$0.41 (1.24%)

As on 01-Sep-2026 16:00EDT

Market cap

$1,023 Mln

Revenue (TTM)

$357 Mln

P/E Ratio

--

P/B Ratio

2.2

Div. Yield

0 %

Edit

	Castle Biosciences (CSTL)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	1,023	12,753	10,906	9,948	9,762
Revenue ($ Mln)	357	1,505	613	785	2,589
Net Profit ($ Mln)	-19.42	160.59	-188.05	41.54	222.40
Net Margin (%)	-5.43	10.67	-30.68	5.29	8.59
RoE (%)	-4.13	10.86	-28.10	1.97	3.04
Price to Earnings	--	79.35	--	251.81	44.47
Price-To-Book	2.22	8.41	16.38	4.86	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Castle Biosciences (CSTL)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	357.28	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	81.25	483.98	127.96	384.30	1,245.50
Gross Profit	273.20	942.44	393.22	347.62	1,343.60
Operating Expenses	308.13	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	-32.11	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-19.20	203.83	-192.83	52.15	350.40
Provision for Tax	0.21	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-19.42	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Castle Biosciences (CSTL)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	470.03	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	34.64	210.18	135.71	705.49	2,116.80
Current Liabilities	56.51	233.78	102.33	132.66	961.30
Total Liabilities	578.56	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	Castle Biosciences (CSTL)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	220.08	630.60	404.74	1,749.63	7,231.50
Current Assets	341.10	1,344.12	515.78	1,200.55	3,020.50
Total Assets	578.56	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	36.65	212.71	102.84	690.94	1,203.70
Net Current Assets	284.59	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	Castle Biosciences (CSTL)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	64.35	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-60.37	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	-6.96	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Castle Biosciences (CSTL)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-4.88	11.76	-22.53	1.79	8.98
ROE (%)	-4.13	10.86	-28.10	1.97	3.04
ROA (%)	-3.20	7.95	-18.00	1.36	2.02
EBIT Margin (%)	-5.27	13.63	-30.58	9.87	-5.99
Net Margin (%)	-5.43	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Castle Biosciences (CSTL)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	3.18	17.55	41.55	16.49	1.37
EBIT Growth (%)	-89.87	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	-105.10	8.72	-102.66	400.42	-30.32
EPS Growth (%)	-82.85	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	0.32	17.33	-12.65	2.16	2.19

Valuation Ratios

	Castle Biosciences (CSTL)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	-47.23	68.93	-34.59	189.42	--
Price / Book Value	2.42	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	77.45	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Castle Biosciences (CSTL)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	0.02	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.01	0.01	0.00	0.01	0.06
Current Ratio	6.04	5.75	5.04	9.05	3.14
Quick Ratio	5.85	3.86	4.46	7.64	2.33
Interest Coverage	-50.21	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	Castle Biosciences (CSTL)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	13.53	12.65	22.67	20.09	17.06
Asset Turnover	0.59	0.74	0.59	0.26	0.24
Receivable days	50.19	46.54	60.95	72.41	65.39
Inventory Days	47.28	331.92	193.84	146.53	221.09
Payable days	65.85	26.16	60.19	29.05	37.02
Cash Conversion Cycle	31.62	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly